What Causes Low ALT Levels and Should You Be Concerned?

Low ALT (alanine aminotransferase) levels are caused by a handful of conditions including vitamin B6 deficiency, chronic kidney disease, loss of muscle mass, and general frailty, particularly in older adults. Most people never hear about low ALT because doctors typically focus on elevated ALT as a sign of liver damage. But research over the past two decades has revealed that unusually low ALT carries its own set of health signals, and in some populations it predicts worse long-term outcomes than mildly elevated levels do.

Why Low ALT Rarely Gets Flagged

ALT is an enzyme found mainly in liver cells, and when those cells are damaged, ALT leaks into the bloodstream and shows up as a high number on a blood panel. That is why most of the medical attention around ALT focuses on the upper end of the range. Standard lab reference ranges typically list a lower limit somewhere around 7 to 10 U/L, and many labs do not even flag results that fall below it. If your result comes back at 5 or 6 U/L, the report might simply say “normal” or show no alert at all.

The clinical habit of ignoring low ALT has deep roots. For decades, the assumption was that ALT only mattered when it was elevated, because elevation pointed toward hepatitis, fatty liver disease, or drug toxicity. A low number was treated as a non-finding. That assumption turns out to be incomplete. ALT is not just a passive bystander that leaks out of damaged cells. It is an active enzyme involved in amino acid metabolism, and its production depends on a healthy liver, adequate nutrition, and sufficient muscle tissue. When any of those inputs falls short, ALT drops, and the drop itself carries information.

The Vitamin B6 Connection

ALT needs a helper molecule to function. That helper is pyridoxal-5-phosphate, the active form of vitamin B6, which serves as a cofactor for both ALT and AST (aspartate aminotransferase, a related liver enzyme).¹ Without enough B6, the enzyme cannot do its job properly, and blood levels of ALT fall even if the liver itself is perfectly healthy. This creates a diagnostic blind spot: a person with genuine liver inflammation could show a falsely “normal” ALT reading if they are also B6-deficient, because the deficiency suppresses the number that would otherwise be elevated.

A study of patients with Parkinson’s disease illustrated this clearly. Researchers found that decreased vitamin B6 levels in these patients showed up as lower AST and ALT readings.² The finding matters beyond Parkinson’s, because B6 deficiency is not rare. Older adults, people with poor dietary intake, heavy alcohol users, and individuals on certain medications (including some used for tuberculosis and epilepsy) are all at higher risk of running low on B6. If you fall into one of those groups and your ALT is unusually low, the B6 link is worth investigating.

The practical implication is straightforward. If low ALT is driven by B6 deficiency, correcting the deficiency should normalize the enzyme level. A simple blood test measuring pyridoxal-5-phosphate can confirm whether B6 is the culprit. Supplementation is inexpensive and generally well tolerated, though it is worth having the conversation with a doctor rather than just self-treating, because very high doses of B6 over long periods can cause nerve problems.

Chronic Kidney Disease Suppresses ALT

People with chronic kidney disease (CKD) consistently show lower ALT levels than people with healthy kidneys, and the more advanced the kidney disease, the lower the ALT tends to go. A comparative study found that patients with end-stage renal disease had a mean ALT of roughly 8 U/L, while those with earlier-stage CKD averaged about 17 U/L, compared to around 27 U/L in healthy controls.³ The differences were statistically striking, and they raise a real clinical concern.

The worry is not the low ALT itself but what it masks. A CKD patient who develops liver disease from hepatitis C, fatty liver, or medication toxicity might not show the usual spike in ALT because their baseline is so suppressed. Their “elevated” ALT of 20 U/L might actually represent a significant jump from a personal baseline of 8, but a clinician scanning for abnormal values would see the 20 and move on. The study’s authors argued that CKD patients need their own separate reference ranges for liver enzymes, precisely because the standard ones can lead to missed diagnoses.

If you have CKD and your ALT readings have always been very low, it is useful to establish what your personal baseline is with your nephrologist. That way, a relative increase from your own norm can be caught even if the absolute number looks unremarkable on a standard lab printout.

Muscle Mass, Frailty, and Aging

ALT is present in the liver, but it also exists in skeletal muscle, kidneys, and other tissues. People with more muscle mass tend to have somewhat higher ALT, and people who have lost significant muscle tend to have lower levels. This relationship becomes especially important in older adults, where muscle loss (sarcopenia) is common and carries serious health consequences including falls, disability, and loss of independence.

A large study of elderly individuals found that reduced ALT levels could be considered a marker of frailty, disability, and sarcopenia, and that low ALT independently predicted worse outcomes over time.⁴ In other words, among older people, a very low ALT was not a sign of a pristinely healthy liver. It was a sign that the body was running low on functional tissue, both in the liver and in skeletal muscle.

This is counterintuitive if you have spent years hearing that lower liver enzyme numbers are always better. For a 35-year-old in good health, a low ALT is almost certainly meaningless. For a 78-year-old who has been losing weight, feels weaker, or has trouble with daily tasks, a low ALT becomes one more data point suggesting that sarcopenia or general frailty may be setting in. The enzyme level does not cause any of these problems; it reflects them. But catching the signal early could prompt interventions like resistance exercise and better protein intake that slow or partly reverse muscle loss.

Low ALT and Mortality Risk

Perhaps the most attention-grabbing finding in this area is the link between low ALT and death. Research has shown that low ALT levels are associated with poor long-term outcomes, serving as a biomarker for increased frailty and a subsequent rise in mortality risk.⁵ This association held after adjusting for age, sex, and other health conditions, suggesting that low ALT is not simply a stand-in for being old or sick but adds independent predictive information.

Before this sends anyone into a panic over a low ALT on their lab report, some context is essential. The mortality association is strongest in older and already-ill populations. It reflects the same underlying processes discussed above: muscle wasting, nutritional deficiency, liver atrophy, and general biological decline. Low ALT is not causing death; it is a downstream signal that the body’s reserves are depleted. Treating a low ALT number by itself would be like trying to raise a fever by putting a thermometer in hot water. The number is the messenger, not the disease.

What the mortality data does suggest is that clinicians should not dismiss a very low ALT in an older or chronically ill patient. Combined with other red flags like unintentional weight loss, decreased grip strength, or slow walking speed, a low ALT can help identify people who would benefit from early nutritional and physical rehabilitation.

Who Should Actually Worry

If you are a younger, generally healthy adult and your ALT comes back at 8 or 10 U/L, there is almost certainly nothing wrong. Normal variation, timing of the blood draw, recent intense exercise, and individual body composition all influence the number. Some people simply run low, and in the absence of symptoms or other abnormal lab results, a low ALT in this population does not warrant further workup.

The picture changes in specific groups:

Adults over 65: A very low ALT, especially if it has been trending downward over time, may signal sarcopenia or frailty. It is worth discussing with a doctor, particularly if you have also noticed weakness, fatigue, or unintended weight loss.
People with chronic kidney disease: Your ALT will naturally run lower than the general population’s. The risk is that liver problems get missed because your “abnormal” still looks normal on the standard scale. Ask your nephrologist about interpreting your liver enzymes in context.
People with known or suspected B6 deficiency: If you are on medications that deplete B6, drink heavily, or have a poor diet, a low ALT may partly reflect inadequate B6 rather than genuine liver or muscle health. Checking your B6 level is a simple next step.
People with Parkinson’s disease or other neurological conditions: B6 metabolism is sometimes disrupted in these populations, and the resulting ALT suppression can complicate the interpretation of liver panels.

For everyone else, the most useful takeaway is awareness. If your doctor orders a comprehensive metabolic panel and the ALT is flagged high, you know that means potential liver stress. Now you also know that an ALT that is very low deserves at least a second look, especially if it is in the single digits and you are in one of the groups listed above.

How ALT Tests Can Mislead Without the Right Calibration

There is a technical wrinkle in ALT testing that most patients never hear about. Some laboratory assays for ALT and AST add pyridoxal-5-phosphate to the reaction mixture, and some do not. When PLP is added, the assay fully activates the enzyme and reflects the body’s true capacity to produce ALT. When PLP is not added, the result depends on whatever B6 the patient happens to have in their blood. This means two labs processing the same blood sample could produce meaningfully different ALT numbers depending on their assay methodology.¹

For a healthy person with adequate B6, the difference between assay types is small and clinically irrelevant. But for someone who is B6-deficient, an assay without PLP supplementation will return a lower ALT than the PLP-supplemented version would. This matters when clinicians use ALT-based scoring systems to assess liver fibrosis or steatosis. A falsely low ALT driven by B6 deficiency rather than by healthy liver tissue could throw off the score and lead to an underestimate of liver damage.

You cannot usually choose which assay your lab uses, but you can ask your doctor whether the lab adds PLP to its aminotransferase assays. If you are in a high-risk group for B6 deficiency and your ALT keeps coming back unusually low, this is a reasonable question to raise. Even if the answer does not change your care, understanding the limitation helps you interpret the numbers more accurately.

Medications and Other Factors That Can Push ALT Down

Beyond the major categories above, a few other situations can contribute to lower-than-expected ALT. Chronic malnutrition from any cause, whether from an eating disorder, malabsorption conditions like celiac disease, or simply inadequate food intake, can reduce the liver’s production of enzymes including ALT. The liver is a metabolically expensive organ, and when the body is deprived of raw materials, enzyme production slows.

Certain medications and supplements may also have modest effects on ALT levels. Drugs that improve liver health, for instance treatments that clear hepatitis C, will bring an elevated ALT back down to normal, but in someone whose ALT was already borderline low, the post-treatment level might dip further. This is usually harmless and reflects the resolution of inflammation, not a new problem.

Regular aerobic exercise, paradoxically, can transiently lower ALT in some people even while building muscle. The effect is generally mild and considered a sign of metabolic health. In the context of an otherwise healthy individual with no risk factors, an exercise-related low ALT is not concerning. It only becomes meaningful if it occurs alongside the risk factors and conditions discussed earlier: advanced age, weight loss, kidney disease, or nutritional deficiency.

The Gap in Standard Reference Ranges

One reason low ALT flies under the radar is that laboratory reference ranges were never designed to catch it. Reference ranges are typically derived from a “healthy” reference population, and the lower bound is set at the 2.5th percentile of that group. Since very few healthy people have clinically significant low ALT, the lower cutoff ends up being extremely low, sometimes in the range of 4 to 7 U/L. A result of 6 U/L might technically fall within the reference range even though it is unusual enough to warrant investigation in certain patient populations.

The study on chronic kidney disease made this point explicitly, arguing that CKD patients need their own reference ranges because applying general-population cutoffs to their results consistently fails to catch meaningful deviations.³ The same argument applies to elderly populations, where an ALT in the single digits may be “within range” but is nonetheless a meaningful marker of frailty and reduced survival.⁴ Until labs adopt population-specific ranges, the burden falls on clinicians and patients to recognize when a “normal” result is actually quietly abnormal for that person.